Merck & Co., Inc.
MRK
Below: live stock price for Merck & Co., Inc. (MRK), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Merck & Co., Inc. (MRK) is a Healthcare company based in United States. Operating in Drug Manufacturers - General, it employs about 73,000 people. Over the past year MRK traded between 82.01 and 156.92 USD. Trailing P/E sits near 151.03 on a market cap of about 368.89B USD. It currently yields 2.27% in dividends.
- Prev close
- $146.33
- Volume (24h)
- $1.84B
- Market cap
- $368.89B
- Currency
- USD
Score
43/ 100 · Weak
- Value2
- Quality67
- Momentum88
- Growth27
- Risk60
- Dividend14
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 149.8311 +0.21%
- +20 bars
- 150.2615 +0.50%
- +60 bars
- 150.4283 +0.61%
- +120 bars
- 150.4345 +0.61%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: 1σ ≈ ±2.33% per bar.
Interpretation
Composite signals look weak. Strength: momentum with weakness: valuation. Price sits near the upper third of the recent range, trend is roughly flat.
Descriptive observation — not investment advice.
Score breakdown
Raw values behind each pillar so you can see what the composite is reading.
- Value2/100
Value looks fragile — driven by P/E (151.03).
P/E:151.03P/B:8.8PEG:2.82 - Quality67/100
Quality looks solid — driven by Gross margin (76.91%).
Profit margin:3.64%Gross margin:76.91% - Momentum88/100
Momentum looks strong — driven by 52w change (81.26%).
52w change:81.26% - Growth27/100
Growth looks fragile — driven by Earnings growth (-12.00%).
Revenue growth:4.70%Earnings growth:-12.00% - Risk60/100
Risk looks solid — driven by Debt / equity (128.41).
Beta:0.22Debt / equity:128.41Short interest:1.09% - Dividend14/100
Dividend looks fragile — driven by Payout ratio (266.67%).
Dividend yield:2.27%Payout ratio:266.67%
Derived from public market data — informational, not investment advice.
Price report
How this asset has actually moved over the last 251 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 29.8%
- Max drawdown
- -11.9%
- Below period high
- -4.7%
- Best day
- +12.60%
- Worst day
- -4.06%
- Up days
- 52%
- Current streak
- 2 up
- Typical day swing
- 2.5%
- Volume vs average
- +21%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 156.92 high → 126.68 low · 60 bars
- ResistanceFib +161.8% extensionnot reached205.8483 USD+37.67% from current
- ResistanceFib +100% extensionnot reached187.16 USD+25.17% from current
- ResistanceFib +61.8% extensionnot reached175.6083 USD+17.45% from current
- ResistanceFib +27.2% extensionnot reached165.1453 USD+10.45% from current
- ResistanceFib 23.6% retracementNearesttested 17×149.7834 USD+0.18% from current
- Current149.52 USD
- SupportFib 38.2% retracementtested 17×145.3683 USD-2.78% from current
- SupportFib 50% midpointtested 9×141.8 USD-5.16% from current
- SupportFib 61.8% retracementnot reached138.2317 USD-7.55% from current
- SupportFib 78.6% retracementtested 2×133.1514 USD-10.95% from current
- SupportFib −27.2% extensionnot reached118.4547 USD-20.78% from current
- SupportFib −61.8% extensionnot reached107.9917 USD-27.77% from current
- SupportFib −100% extensionnot reached96.44 USD-35.50% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Financials
- 52w high
- $156.92
- 52w low
- $82.01
- 52w change
- 81.26%
- Day high
- $151.35
- Day low
- $147.43
- P/E (TTM)
- 151.03
- Forward P/E
- 16.39
- PEG
- 2.82
- Price / Book
- 8.8
- Beta (5Y)
- 0.22
- Enterprise value
- 415.71B
- EV / Revenue
- 6.17
- EV / EBITDA
- 26.04
- EPS (TTM)
- $0.99
- Forward EPS
- $9.12
- Dividend yield
- 2.27%
- Dividend rate
- $3.40
- Payout ratio
- 266.67%
- Revenue (TTM)
- 67.38B
- EBITDA
- 15.96B
- Total cash
- 7.14B
- Total debt
- 53.91B
- Debt / Equity
- 128.41
- Profit margin
- 3.64%
- Gross margin
- 76.91%
- Shares outstanding
- 2.47B
- Float
- 2.46B
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Analyst & Risk
Analysts' consensus via Yahoo Finance — not investment advice.
- Beta (vs S&P 500)
- 0.22
- very stable
- 52-week change
- 81.26%
- Short % of float
- 1.09%
- Short ratio (days)
- 2.68
- Debt / Equity
- 128.41
- very high leverage
- PEG ratio
- 2.82
- EV / Revenue
- 6.17
- EV / EBITDA
- 26.04
- Revenue growth
- 4.70%
- Earnings growth
- -12.00%
- EBITDA
- 15.96B
- Total cash
- 7.14B
- Total debt
- 53.91B
- Insider holdings
- 0.06%
- Institutional
- 82.88%
Recent rating changes
- 2026-10-30JP MorganOverweight → Overweightmain
- 2026-10-30RBC CapitalSector Perform → Sector Performmain
- 2026-10-30GuggenheimBuy → Buymain
- 2026-10-26BarclaysOverweight → Overweightmain
- 2026-10-12CitigroupNeutral → Neutralmain
- 2026-10-12RBC CapitalSector Perform → Sector Performmain
- 2026-10-08Cantor FitzgeraldNeutral → Neutralmain
- 2026-10-07Morgan StanleyOverweight → Overweightmain
Financial documents
- Corporate Changes & Voting Matters8-K2026-10-29
- Notification filed by national security exchange to report the removal from listing and registration of matured25-NSE2026-10-15
- Corporate Changes & Voting Matters8-K2026-10-13
- Corporate Changes & Voting Matters8-K2026-08-04
- Annual report of employee stock purchase11-K2026-06-24
- Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)SD2026-05-29
- Corporate Changes & Voting Matters8-K2026-05-28
- Corporate Changes & Voting Matters8-K2026-05-22
- Tender Offer/Acquisition ReportsSC TO-T/A2026-05-05
- Periodic Financial Reports10-Q2026-05-04
- Corporate Changes & Voting Matters8-K2026-04-30
- Proxy StatementsDEF 14A2026-04-08
Recent news
- How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine DataSimply Wall St.10 hr. ago
- Merck (MRK) Stock Rallies As Q3 Earnings Ease Profit SqueezeSimply Wall St.17 hr. ago
- Why Merck Stock Flew Higher on FridayMotley Fool19 hr. ago
- Merck Stocks Rise 2.6% With Qlex Still Under 10% of Keytruda SalesGuruFocus.com23 hr. ago
- Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs24/7 Wall St.yesterday
- CMMB Celebrates New Distribution Center at the Brethren Service Center with Ribbon-Cutting CeremonyGlobeNewswireyesterday
- This week in charts: ESMO’s winners and losersBioPharma Diveyesterday
- EXEL Q3 Earnings Beat Estimates on Strong Cabometyx SalesZacksyesterday
Related
Other assets in this category.
Learn the terms
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.